Cue Biopharma, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.9M | $5.7M | $21.9M | $2.1M | $3.0M | $421.0K | $1.6M | $3.3M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $49.0M | $6.9M | $16.5M | $4.8M | $7.9M | $8.5M | $7.2M | $9.4M |
| SG&A Expense | $46.6M | $4.2M | $3.5M | $4.9M | $3.7M | $4.2M | $4.0M | $2.9M |
| Operating Income | $-87.7M | $-5.4M | $2.0M | $-7.6M | $-8.6M | $-12.3M | $-9.6M | $-8.8M |
| Operating Margin | -1,113.3% | -94.1% | 9.0% | -353.4% | -292.3% | -2,921.4% | -611.3% | -264.2% |
| Interest Expense | — | — | — | — | $33.0K | $100.0K | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-153.1M | $-5.2M | $1.6M | $-7.4M | $-8.5M | $-12.3M | $-9.5M | $-8.7M |
| Net Margin | -1,943.2% | -91.1% | 7.2% | -346.6% | -287.1% | -2,911.4% | -602.5% | -259.6% |
| EPS (Basic) | $-24.14 | $-1.08 | $7.41 | $-0.07 | $-2.67 | $-4.95 | $-0.10 | $-0.17 |
| EPS (Diluted) | $-24.14 | $-1.08 | $7.41 | $-0.07 | $-2.67 | $-4.95 | $-0.10 | $-0.17 |
| Shares Outstanding (Basic) | 6.3M | 4.8M | 94.7M | 100.9M | 3.2M | 2.5M | 56.3M | 51.2M |
| Shares Outstanding (Diluted) | 6.3M | 4.8M | 94.7M | 100.9M | 3.2M | 2.5M | 56.3M | 51.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |